汇宇制药迎上市以来首亏，第二大股东遭强执

Core Viewpoint - Huiyu Pharmaceutical is expected to report a significant decline in revenue and net profit for the year 2025, marking its first loss since its listing in 2021 [1] Group 1: Financial Performance - The company forecasts a revenue range of 960 million to 1.09 billion yuan for 2025, representing a year-on-year decline of 12.28% to 0.40% [1] - The projected net profit attributable to the parent company is expected to be a loss between 29 million and 24 million yuan, indicating a year-on-year decline of 108.91% to 107.38% [1] - Historical net profits from 2021 to 2024 were 446 million, 249 million, 140 million, and 325 million yuan respectively [1] Group 2: Reasons for Loss - The anticipated loss is primarily attributed to fair value changes resulting from the stock price fluctuations of Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which was listed on the Hong Kong Stock Exchange on August 20, 2024 [1] Group 3: Shareholder Developments - Prior to the earnings warning, the company disclosed that its second-largest shareholder, Huang Qianyi, would face judicial forced reduction of shares [1] - Huang Qianyi is the son of Huang Bingquan, one of the core founders of Huiyu Pharmaceutical [1] Group 4: Market Reaction - On January 29, the company's stock fell by 2.74%, with a total market capitalization of 8.112 billion yuan, marking a cumulative decline of over 8% over five consecutive days [2]